Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 1
1958 1
1968 3
1969 1
1970 3
1972 1
1973 4
1974 2
1975 4
1976 4
1977 5
1978 4
1979 3
1980 4
1981 7
1982 15
1983 6
1984 7
1985 8
1986 14
1987 12
1988 12
1989 16
1990 28
1991 26
1992 21
1993 26
1994 34
1995 46
1996 66
1997 55
1998 44
1999 54
2000 64
2001 52
2002 79
2003 83
2004 94
2005 107
2006 87
2007 90
2008 117
2009 93
2010 91
2011 116
2012 124
2013 134
2014 138
2015 108
2016 126
2017 109
2018 103
2019 139
2020 147
2021 140
2022 128
2023 99
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

2,829 results

Results by year

Filters applied: . Clear all
Page 1
Celecoxib in Cancer Therapy and Prevention - Review.
Tołoczko-Iwaniuk N, Dziemiańczyk-Pakieła D, Nowaszewska BK, Celińska-Janowicz K, Miltyk W. Tołoczko-Iwaniuk N, et al. Curr Drug Targets. 2019;20(3):302-315. doi: 10.2174/1389450119666180803121737. Curr Drug Targets. 2019. PMID: 30073924 Review.
The vast majority of publications refers to preclinical studies attempting to elucidate its mechanisms of action. Clinical trials concerning celecoxib have focused primarily on the treatment of cancers of the colon, breast, lung, prostate, stomach, head and neck, as well a …
The vast majority of publications refers to preclinical studies attempting to elucidate its mechanisms of action. Clinical trials con …
Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
Cheng X, Xu X, Chen D, Zhao F, Wang W. Cheng X, et al. Biomed Pharmacother. 2019 Feb;110:473-481. doi: 10.1016/j.biopha.2018.11.082. Epub 2018 Dec 6. Biomed Pharmacother. 2019. PMID: 30530050 Free article. Review.
Approximately 80% of CRC cases harbor mutations in the adenomatous polyposis coli gene, and half of the remaining cases feature mutations in the beta-catenin gene that affect the Wnt/beta-catenin signaling pathway. ...
Approximately 80% of CRC cases harbor mutations in the adenomatous polyposis coli gene, and half of the remaining cases feature mutat …
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, Tversky JR, Barker P, Cohen D, Emson C, Martin UJ, Shih VH, Necander S, Kreindler JL, Jison M, Werkström V. Bachert C, et al. J Allergy Clin Immunol. 2022 Apr;149(4):1309-1317.e12. doi: 10.1016/j.jaci.2021.08.030. Epub 2021 Sep 29. J Allergy Clin Immunol. 2022. PMID: 34599979 Clinical Trial.
Coprimary end points were change from baseline to week 40 in NP score (NPS) and patient-reported mean nasal blockage score reported once every 2 weeks. RESULTS: The study population comprised 413 randomized patients (207 in the benralizumab group and 206 in the placebo gro …
Coprimary end points were change from baseline to week 40 in NP score (NPS) and patient-reported mean nasal blockage score reported once eve …
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
SNOT-22 was summarised for the subgroup of patients with physician-diagnosed nasal polyposis with informed consent. This study is registered with ClinicalTrials.gov, NCT03170271. ...INTERPRETATION: Our results extend the efficacy profile of benralizumab for patients with s …
SNOT-22 was summarised for the subgroup of patients with physician-diagnosed nasal polyposis with informed consent. This study is reg …
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pirozzi G, Mannent L, Graham NMH. Hamilton JD, et al. Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26. Clin Exp Allergy. 2021. PMID: 34037993 Free PMC article.
OBJECTIVE: Assessment of dupilumab effect on type 2 inflammatory biomarkers in atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic esophagitis (EoE). METHODS: Data were extracted from three randomized placebo-controlled trials …
OBJECTIVE: Assessment of dupilumab effect on type 2 inflammatory biomarkers in atopic dermatitis (AD), asthma, chronic rhinosinusitis with n …
Dupilumab for the treatment of asthma.
Pelaia C, Vatrella A, Gallelli L, Terracciano R, Navalesi P, Maselli R, Pelaia G. Pelaia C, et al. Expert Opin Biol Ther. 2017 Dec;17(12):1565-1572. doi: 10.1080/14712598.2017.1387245. Epub 2017 Oct 8. Expert Opin Biol Ther. 2017. PMID: 28990423 Review.
They also review: the mechanism of action of dupilumab, the phase I, II and III studies evaluating the pharmacokinetics as well as the safety, tolerability and clinical efficacy of dupilumab in asthma therapy. Expert opinion: Supported by a strategic mechanism of action, a …
They also review: the mechanism of action of dupilumab, the phase I, II and III studies evaluating the pharmacokinetics as well as the safet …
Dupilumab: First Global Approval.
Shirley M. Shirley M. Drugs. 2017 Jul;77(10):1115-1121. doi: 10.1007/s40265-017-0768-3. Drugs. 2017. PMID: 28547386 Review.
In addition, dupilumab is currently under phase III development across the world for the treatment of asthma and nasal polyposis as well as for atopic dermatitis in paediatric patients. ...
In addition, dupilumab is currently under phase III development across the world for the treatment of asthma and nasal polyposis as w …
Chemoprevention of colorectal neoplasia.
Wakeman C, Keenan J, Eteuati J, Hollington P, Eglinton T, Frizelle F. Wakeman C, et al. ANZ J Surg. 2017 Dec;87(12):E228-E232. doi: 10.1111/ans.13392. Epub 2015 Dec 21. ANZ J Surg. 2017. PMID: 26686322 Review.
METHODS: An electronic literature search of MEDLINE and Embase databases was performed on PubMed for studies detailing the use of chemoprevention agents in colon and rectal cancer. The search was limited to clinical trials on adult humans (>16 years of age) published in …
METHODS: An electronic literature search of MEDLINE and Embase databases was performed on PubMed for studies detailing the use of chemopreve …
Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome.
Stone JK, Mehta NA, Singh H, El-Matary W, Bernstein CN. Stone JK, et al. Fam Cancer. 2023 Oct;22(4):413-422. doi: 10.1007/s10689-023-00334-3. Epub 2023 Apr 29. Fam Cancer. 2023. PMID: 37119510 Review.
Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome predisposing affected individuals to gastrointestinal (GI) cancers through a high burden of polyposis. ...While data remains limited on chemoprevention in FAP, a number of randomized trial …
Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome predisposing affected individuals to gastrointestinal (GI) can …
A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
Miglani A, Soler ZM, Smith TL, Mace JC, Schlosser RJ. Miglani A, et al. Int Forum Allergy Rhinol. 2023 Feb;13(2):116-128. doi: 10.1002/alr.23059. Epub 2022 Sep 4. Int Forum Allergy Rhinol. 2023. PMID: 35980852 Free PMC article.
BACKGROUND: Comparative effectiveness research between endoscopic sinus surgery (ESS) and biologic therapy for severe chronic rhinosinusitis with nasal polyposis (CRSwNP) is a nascent field as new therapeutic modalities become clinically available. METHODS: A prospective, …
BACKGROUND: Comparative effectiveness research between endoscopic sinus surgery (ESS) and biologic therapy for severe chronic rhinosinusitis …
2,829 results